Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 1/20 | 0.40 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.40 |
| ▸ | ADORA2B | P29275 | 4/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.38 |
| ▸ | NPY5R | Q15761 | 5/20 | 0.37 |
| ▸ | PTGES | O14684 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | BRAF | P15056 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 3/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | STAT1 | P42224 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | NQO2 | P16083 | 2/20 | 0.37 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.37 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3787488 | 0.91 | CYP11B1 (0.38) | CYP11B1ADORA2BCYP3A4CYP2C19NPY5R | |
| SCHEMBL3786530 | 0.90 | CYP11B1 (0.49) | CYP11B1ADORA2BCYP3A4CYP2C19NPY5R | |
| SCHEMBL3794517 | 0.88 | NPY5R (0.47) | CYP11B1ADORA2BCYP3A4CYP2C19NPY5R | |
| SCHEMBL3791710 | 0.88 | CYP11B1 (0.44) | CYP11B1ADORA2BCYP3A4CYP2C19NPY5R | |
| SCHEMBL3794532 | 0.87 | CYP11B1 (0.44) | CYP11B1ADORA2BCYP3A4CYP2C19NPY5R | |
| SCHEMBL3790745 | 0.86 | CYP11B1 (0.48) | CYP11B1ADORA2BCYP3A4CYP2C19NPY5R | |
| SCHEMBL3786314 | 0.85 | CYP11B1 (0.41) | CYP11B1ADORA2BCYP3A4CYP2C19NPY5R | |
| SCHEMBL3792218 | 0.85 | CYP11B1 (0.47) | CYP11B1ADORA2BCYP3A4CYP2C19NPY5R | |
| SCHEMBL3791679 | 0.84 | METAP2 (0.42) | CYP11B1ADORA2BCYP3A4CYP2C19NPY5R | |
| SCHEMBL3786289 | 0.83 | METAP2 (0.46) | CYP11B1ADORA2BCYP3A4CYP2C19NPY5R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7855202-B2 | Imidazopyridine derivatives as A2B adenosine receptor antagonists | LABORATORIOS ALMIRALL, S.A. (ES) | 2010-12-21 | — | — | US | claimed |
| US-20080275038-A1 | Imidazopyridine Derivatives as A2b Adenosine Receptor Antagonists | LABORATORIOS ALMIRALL, S.A. (ES) | 2008-11-06 | — | — | US | claimed |
| US-7855202-B2 | Imidazopyridine derivatives as A2B adenosine receptor antagonists | LABORATORIOS ALMIRALL, S.A. (ES) | 2010-12-21 | — | — | US | disclosed |
| US-7855202-B2 | Imidazopyridine derivatives as A2B adenosine receptor antagonists | LABORATORIOS ALMIRALL, S.A. (ES) | 2010-12-21 | — | — | US | disclosed |
| US-7855202-B2 | Imidazopyridine derivatives as A2B adenosine receptor antagonists | LABORATORIOS ALMIRALL, S.A. (ES) | 2010-12-21 | — | — | US | disclosed |
| US-20080275038-A1 | Imidazopyridine Derivatives as A2b Adenosine Receptor Antagonists | LABORATORIOS ALMIRALL, S.A. (ES) | 2008-11-06 | — | — | US | disclosed |
| US-20080275038-A1 | Imidazopyridine Derivatives as A2b Adenosine Receptor Antagonists | LABORATORIOS ALMIRALL, S.A. (ES) | 2008-11-06 | — | — | US | disclosed |
| US-20080275038-A1 | Imidazopyridine Derivatives as A2b Adenosine Receptor Antagonists | LABORATORIOS ALMIRALL, S.A. (ES) | 2008-11-06 | — | — | US | disclosed |
| WO-2007039297-A1 | IMIDAZOPYRIDINE DERIVATIVES AS A2B ADENOSINE RECEPTOR ANTAGONISTS | LABORATORIOS ALMIRALL, S.A. (ES) | 2007-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080275038-A1 | Imidazopyridine Derivatives as A2b Adenosine Receptor Antagonists | ADORA2B, ADORA2A, ADORA1 | IDO1 989/4885CYP11B1 327/4885ADORA2B 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.